Targeting Estrogen Receptor (ER) Mutations for Treatment of Endocrine Therapy Resistance in Breast Cancer

被引：1
|
作者：
Alluri, P. G. [1 ]
Larios, J. [1 ]
Malik, R. [1 ]
Rae, J. [1 ]
Chinnaiyan, A. [2 ]
机构：
[1] Univ Michigan, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Ctr Canc, Ann Arbor, MI 48109 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2016年 / 96卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2016.06.139
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
118
引用
收藏
页码：S53 / S53
页数：1
相关论文
共 50 条
  • [31] Adjuvant endocrine treatment for estrogen receptor (ER)-positive/HER2-negative breast cancer
    Kubo, Makoto
    CHINESE CLINICAL ONCOLOGY, 2020, 9 (03)
  • [32] Identification of novel kinases involved in Estrogen receptor-α (ERα) signalling and the development of endocrine resistance in breast cancer
    Giamas, Georgios
    Zhang, Hua
    Zhang, Wu
    Filipovic, Aleksandra
    Lenz, Heinz-Josef
    Stebbing, Justin
    CANCER RESEARCH, 2012, 72
  • [33] Dual targeting of estrogen receptor α and estrogen-related receptor α: a novel endocrine therapy for endometrial cancer
    Mao, XiaoDan
    Dong, Binhua
    Gao, Min
    Ruan, GuanYu
    Huang, MeiMei
    Braicu, Elena Loana
    Sehouli, Jalid
    Sun, PengMing
    ONCOTARGETS AND THERAPY, 2019, 12 : 6757 - 6767
  • [34] Vandetanib to Overcome Endocrine Resistance in Estrogen Receptor Positive Breast Cancer
    Kakati, Rasha
    Whitman, Austin A.
    Kim, Hyunsoo
    Molina, Sarahi G.
    Beltran, Adriana S.
    Spanheimer, Philip M.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2022, 235 (05) : S6 - S7
  • [35] Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer
    Osborne, CK
    Shou, J
    Massarweh, S
    Schiff, R
    CLINICAL CANCER RESEARCH, 2005, 11 (02) : 865S - 870S
  • [36] Endocrine resistance and epigenetic reprogramming in estrogen receptor positive breast cancer
    Dimitrakopoulos, Foteinos-Ioannis
    Kottorou, Anastasia
    Tzezou, Aspasia
    CANCER LETTERS, 2021, 517 : 55 - 65
  • [37] Phosphorylation Status of Estrogen Receptor Alpha and Endocrine Resistance in Breast Cancer
    Kim, K.
    Katzenellenbogen, B. S.
    ENDOCRINE REVIEWS, 2010, 31 (03)
  • [38] Nuclear FGFR1 interaction with estrogen receptor (ER) α is associated with resistance to endocrine therapy in ER+/FGFR1-amplified breast cancer
    Formisano, L.
    Young, C. D.
    Bhola, N. E.
    Bulen, B.
    Estrada, V. M.
    Wagle, N.
    Van Allen, E.
    Brewer, M. L. Red
    Jansen, V. M.
    Guerrero, A. L.
    Giltnane, J. M.
    Strcker, T.
    Arteaga, C. L.
    CANCER RESEARCH, 2016, 76
  • [39] Neoadjuvant endocrine therapy for estrogen receptor (ER) positive breast cancer: Comprehensive systematic review and meta -analysis
    Spring, L.
    Gupta, A.
    Reynolds, K. L.
    Gadd, M. A.
    Isakoff, S. J.
    Ellisen, L. W.
    Moy, B.
    Bardia, A.
    CANCER RESEARCH, 2016, 76
  • [40] ESTROGEN-RECEPTOR (ER) STATUS OF PRIMARY BREAST-CANCER AND RESPONSE OF SECONDARY DISEASE TO ENDOCRINE THERAPY
    CAMPBELL, FC
    BLAMEY, RW
    MORRIS, AH
    NICHOLSON, RI
    GRIFFITHS, K
    CLINICAL ONCOLOGY, 1982, 8 (01): : 85 - 86
12345